A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

NCT05383170 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Head and Neck Squamous Cell Carcinoma
Advanced Breast Cancer
Advanced Melanoma

Interventions

DRUG: CyPep-1
DRUG: Pembrolizumab 25 MG/ML [KEYTRUDA®]

Sponsor

Cytovation AS

Collaborators

[object Object]